Search results
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...
KOLR - KSFX Ozarks· 3 days agoOlomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein.
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
FOX Business· 4 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Cullinan Therapeutics announces success for zipalertinib as combo therapy
Clinical Trials Arena via Yahoo Finance· 1 day agoCullinan Therapeutics has announced positive topline data from a Phase I/II trial of its pipeline...
Bristol’s $250,000 Pill Slows Lung Cancer Growth by Seven Weeks
Bloomberg· 3 days agoHave a confidential tip for our reporters? A Bristol Myers Squibb Co. lung cancer treatment delayed ...
Tempus launches new HER2 and FOLR1 testing solutions
Medical Device Network via Yahoo Finance· 1 day agoThe two companies are currently building on a pilot programme that uses Next, Tempus' care pathway intelligence platform, to help doctors decide whether...
Lorlatinib: ‘Unprecedented’ pill slows lung cancer in 60% of cases
Interesting Engineering· 1 day agoALK-positive NSCLC tends to be more aggressive and is often found in younger individuals with little to no smoking history. Lorlatinib is a third-generation ALK inhibitor. It is the latest in ...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 2 days agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
Novel targeted cancer therapies demonstrate activity and safety in metastatic solid tumors
Medical Xpress· 20 hours agoPreliminary data from a Phase I study evaluating the novel antibody-drug conjugate (ADC) M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal
Lack of insurance may prevent Americans from accessing best cancer drugs
United Press International via Yahoo News· 23 hours agoA cutting-edge class of drugs is saving and extending the lives of cancer patients. But the drugs,...
Lack of insurance keeps many Americans from best cancer meds
Medical Xpress· 1 day agoThe study was led by ACS researcher Dr. Jingxuan Zhao. ICIs include such blockbuster cancer...
